CDH1 and ovarian cancer: However, recent studies have challenged this dogma and shown that loss of E-cadherin in ovarian cancer cell lines decreases migration [80], while metastasized breast cancers exhibit greater expression of E-cadherin, or begin to re-express it during a reverting transition compared to primary cancer cells [81, 82].